CDXC ChromaDex Corp

Price (delayed)

$1.52

Market cap

$113.95M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.15

Enterprise value

$94.89M

ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create ...

Highlights
The company's EPS has surged by 62% YoY and by 38% QoQ
The company's net income has surged by 61% YoY and by 35% QoQ
The equity rose by 8% year-on-year but it has declined by 2.3% since the previous quarter
CDXC's gross margin is down by 3.1% year-on-year

Key stats

What are the main financial stats of CDXC
Market
Shares outstanding
74.97M
Market cap
$113.95M
Enterprise value
$94.89M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.06
Price to sales (P/S)
1.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.23
Earnings
Revenue
$77.35M
EBIT
-$10.78M
EBITDA
-$9M
Free cash flow
-$5.51M
Per share
EPS
-$0.15
Free cash flow per share
-$0.07
Book value per share
$0.37
Revenue per share
$1.03
TBVPS
$0.71
Balance sheet
Total assets
$53.77M
Total liabilities
$25.75M
Debt
$4.09M
Equity
$28.02M
Working capital
$28.14M
Liquidity
Debt to equity
0.15
Current ratio
2.53
Quick ratio
1.76
Net debt/EBITDA
2.12
Margins
EBITDA margin
-11.6%
Gross margin
59.2%
Net margin
-13.8%
Operating margin
-16.6%
Efficiency
Return on assets
-21.4%
Return on equity
-43.5%
Return on invested capital
-61.7%
Return on capital employed
-30.5%
Return on sales
-13.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CDXC stock price

How has the ChromaDex stock price performed over time
Intraday
2.01%
1 week
6.29%
1 month
10.14%
1 year
-19.15%
YTD
-9.52%
QTD
-0.65%

Financial performance

How have ChromaDex's revenue and profit performed over time
Revenue
$77.35M
Gross profit
$45.78M
Operating income
-$12.86M
Net income
-$10.7M
Gross margin
59.2%
Net margin
-13.8%
ChromaDex's net margin has soared by 65% YoY and by 40% from the previous quarter
The company's net income has surged by 61% YoY and by 35% QoQ
CDXC's operating margin has surged by 58% year-on-year and by 36% since the previous quarter
ChromaDex's operating income has surged by 53% YoY and by 31% QoQ

Growth

What is ChromaDex's growth rate over time

Valuation

What is ChromaDex stock price valuation
P/E
N/A
P/B
4.06
P/S
1.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.23
The company's EPS has surged by 62% YoY and by 38% QoQ
CDXC's price to book (P/B) is 59% lower than its 5-year quarterly average of 9.9 and 10% lower than its last 4 quarters average of 4.5
The equity rose by 8% year-on-year but it has declined by 2.3% since the previous quarter
CDXC's price to sales (P/S) is 71% lower than its 5-year quarterly average of 5.1 and 2% lower than its last 4 quarters average of 1.5
The revenue has grown by 10% YoY and by 7% from the previous quarter

Efficiency

How efficient is ChromaDex business performance
CDXC's return on invested capital has surged by 67% year-on-year and by 33% since the previous quarter
The company's return on sales has surged by 65% YoY and by 40% QoQ
ChromaDex's return on assets has surged by 54% YoY and by 36% QoQ
The company's return on equity rose by 46% YoY and by 37% QoQ

Dividends

What is CDXC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CDXC.

Financial health

How did ChromaDex financials performed over time
The total assets is 109% more than the total liabilities
CDXC's quick ratio is up by 21% year-on-year and by 9% since the previous quarter
The current ratio has increased by 6% year-on-year but it has declined by 3.1% since the previous quarter
ChromaDex's debt is 85% less than its equity
CDXC's debt to equity is down by 17% year-on-year
ChromaDex's debt has decreased by 12% YoY and by 4% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.